Sugi Predict

Sugi Predict / Compounds / SCHEMBL904049

SCHEMBL904049

SCHEMBL904049

CC(C)(C)OC(=O)N1CC=C(c2ccc(O)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.61
▸ PDK4 Q16654 1/20 0.57
▸ GRM1 Q13255 10/20 0.54
▸ GRM5 P41594 10/20 0.54
▸ ESR2 Q92731 1/20 0.53
▸ QDPR P09417 2/20 0.51
▸ CDK7 P50613 1/20 0.49
▸ CDK13 Q14004 1/20 0.49
▸ CDK12 Q9NYV4 1/20 0.49
▸ HTR6 P50406 1/20 0.49
▸ GPR119 Q8TDV5 1/20 0.48
▸ CYP11B2 P19099 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8912847 0.90 NAMPT (0.63) NAMPTPDK4GRM1GRM5CDK7
SCHEMBL16149998 0.89 NAMPT (0.54) NAMPTPDK4GRM1GRM5ESR2
SCHEMBL30191435 0.89 CYP11B2 (0.61) NAMPTPDK4GRM1GRM5ESR2
SCHEMBL2908091 0.88 NAMPT (0.60) NAMPTPDK4GRM1GRM5CDK7
SCHEMBL18619845 0.88 NAMPT (0.60) NAMPTPDK4GRM1GRM5CDK7
SCHEMBL18619842 0.88 NAMPT (0.60) NAMPTPDK4GRM1GRM5CDK7
SCHEMBL652961 0.88 NAMPT (0.60) NAMPTPDK4GRM1GRM5CDK7
SCHEMBL2594283 0.88 GRM1 (0.65) NAMPTPDK4GRM1GRM5
SCHEMBL29227506 0.88 NAMPT (0.60) NAMPTPDK4GRM1GRM5CDK7
SCHEMBL578028 0.88 NAMPT (0.60) NAMPTPDK4GRM1GRM5CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD SAINT LOUIS UNIVERSITY (US) 2026-05-26 — — US disclosed
WO-2026102147-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. (US) 2026-05-15 — — WO disclosed
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
US-12310975-B2 Modulators of BCL6 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2025-05-27 — — US disclosed
CN-119019369-A Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety 阿尔维纳斯运营股份有限公司 2024-11-26 — — CN disclosed
CN-115397821-B Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety 阿尔维纳斯运营股份有限公司 2024-09-03 — — CN disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
CN-115397821-A Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety 阿尔维纳斯运营股份有限公司 2022-11-25 — — CN disclosed
US-20220323457-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-13 — — US disclosed
EP-4045496-A1 BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY Arvinas Operations, Inc. (US) 2022-08-24 — — EP disclosed
WO-2012041158-A1 TRICYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF 上海恒瑞医药有限公司 (CN) 2012-04-05 — — WO disclosed
WO-2010048149-A2 HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-04-29 — — WO disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 — — US disclosed
EP-1957073-A2 MEDICINAL DRUG OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-08-20 — — EP disclosed
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 — — EP disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 — — US disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 — — WO disclosed
EP-1773797-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-04-18 — — EP disclosed
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof NOVARTIS AG (CH) 2006-11-02 — — US disclosed
WO-2006014012-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof DPYD, P2RY1, P2RY2 NAMPT 1174/4885PDK4 1077/4885GRM1 1708/4885
US-12310975-B2 Modulators of BCL6 proteolysis and associated methods of use BCL6, BCL6B, BCL3 NAMPT 4087/4885PDK4 3577/4885GRM1 3962/4885
US-20220323457-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 NAMPT 4087/4885PDK4 3577/4885GRM1 3962/4885
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 NAMPT 3393/4885PDK4 1574/4885GRM1 1069/4885
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD BRDT, BET1, PHKB NAMPT 4003/4885PDK4 1495/4885GRM1 3550/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 NAMPT 4432/4885PDK4 2158/4885GRM1 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.